Vaccination of Monkeys with RecombinantPlasmodium falciparumApical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria
Open Access
- 1 December 2002
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (12), 6961-6967
- https://doi.org/10.1128/iai.70.12.6961-6967.2002
Abstract
A major challenge facing malaria vaccine development programs is identifying efficacious combinations of antigens. To date, merozoite surface protein 1 (MSP1) is regarded as the leading asexual vaccine candidate. Apical membrane antigen 1 (AMA1) has been identified as another leading candidate for an asexual malaria vaccine, but without any direct in vivo evidence that a recombinant form ofPlasmodium falciparumAMA1 would have efficacy. We evaluated the efficacy of a form ofP. falciparumAMA1, produced inPichia pastoris, by vaccinatingAotus vociferansmonkeys and then challenging them withP. falciparumparasites. Significant protection from this otherwise lethal challenge withP. falciparumwas observed. Five of six animals had delayed patency; two of these remained subpatent for the course of the infection, and two controlled parasite growth at <0.75% of red blood cells parasitized. The protection induced by AMA1 was superior to that obtained with a form of MSP1 used in the same trial. The protection induced by a combination vaccine of AMA1 and MSP1 was not superior to the protection obtained with AMA1 alone, although the immunity generated appeared to operate against both vaccine components.Keywords
This publication has 20 references indexed in Scilit:
- The Mechanism and Significance of Deletion of Parasite-specific CD4+T Cells in Malaria InfectionThe Journal of Experimental Medicine, 2002
- Merozoite Surface Protein 3 and Protection against Malaria inAotus nancymaiMonkeysThe Journal of Infectious Diseases, 2002
- Specificity of the Protective Antibody Response to Apical Membrane Antigen 1Infection and Immunity, 2001
- Efficacy of Two Alternate Vaccines Based onPlasmodium falciparumMerozoite Surface Protein 1 in anAotusChallenge TrialInfection and Immunity, 2001
- Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect MosquitoesInfection and Immunity, 2000
- Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoelii YM Blood-Stage InfectionInfection and Immunity, 2000
- Immunogenicity and Efficacy inAotusMonkeys of Four RecombinantPlasmodium falciparumVaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1Infection and Immunity, 2000
- Vaccine Efficacy of RecombinantPlasmodium falciparumMerozoite Surface Protein 1 in Malaria-Naive, -Exposed, and/or -RechallengedAotus vociferansMonkeysInfection and Immunity, 2000
- A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infectionImmunological Reviews, 1999
- Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigenParasite Immunology, 1988